Clinical evaluation of fleroxacin in the treatment of bone and joint infections

Y. C. Liu, D. L. Cheng, C. Y. Liu, S. T. De Garis, H. H. Lin, T. L. Hsieh, M. Y. Yen, R. S. Wang, Y. S. Chen

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


The objective of this open label, non-comparative study was to evaluate the efficacy and safety of fleroxacin 400mg administered orally once daily to patients with acute osteomyelitis and/or acute septic arthritis. Nineteen patients (10 males and 9 females) were evaluable for the analysis of clinical efficacy and safety. Of these, 7 (36.8%) had osteomyelitis and 12 (63.2%) had septic arthritis. Bacteriological cures were reported in 6 of 7 patients (85.7%) with osteomyelitis and in 8 of 11 patients (72.11%) with septic arthritis. The median duration of treatment for the clinical cures in osteomyelitis and septic arthritis were 29.5 days and 46 days respectively. The eradication rate for the most common pathogens, Salmonella enteritidis and Staphylococcus aureus were 77.7% and 80.0%, respectively. The clinical response was cure in 4 of 7 patients (57.1%) evaluable for osteomyelitis, and in 9 of 12 patients (75.0%) evaluable for septic arthritis at the three-month follow-up after treatment. Adverse reactions were minimal. It is concluded that fleroxacin appears to be an effective and safe in the treatment of acute osteomyelitis and acute septic arthritis.

Original languageEnglish
Pages (from-to)514-519
Number of pages6
JournalSoutheast Asian Journal of Tropical Medicine and Public Health
Issue number3
Publication statusPublished - 1992
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Clinical evaluation of fleroxacin in the treatment of bone and joint infections'. Together they form a unique fingerprint.

Cite this